Back to Search Start Over

Pretreatment of microneedles enhances passive transdermal administration of pilocarpine and pilocarpine-induced sweat production in humans.

Authors :
Amano T
Fujii N
Kenny GP
Mündel T
Yokoyama S
Yamashita H
Quan YS
Source :
International journal of pharmaceutics [Int J Pharm] 2024 Sep 05; Vol. 662, pp. 124497. Date of Electronic Publication: 2024 Jul 19.
Publication Year :
2024

Abstract

The development of an effective transdermal drug delivery protocol to eccrine sweat glands is important for the advancement of research on the human sweating response. We investigated whether microneedle treatment prior to the application of pilocarpine, a hydrophilic and sudorific agent that does not induce sweating due to a limited percutaneous passive diffusion by skin application alone, augments sweat production. We applied three microneedle arrays to forearm skin sites simultaneously (n = 20). Upon removal of the microneedles, 1 % pilocarpine was applied to each site for 5-, 15-, and 30-min for the assessment of sweat gland function. In parallel, pilocarpine was administered by transdermal iontophoresis (5-min) at a separate site. Sweat rate was assessed continuously via the ventilated capsule technique. Pilocarpine augmented sweat rate at the 15- and 30-min periods as compared to the application at 5-min. The sweating responses induced by the 15- and 30-min application of pilocarpine were equivalent to ∼ 80 % of that measured at the iontophoretically treated sites. Notably, we observed a correlation in sweat rate between these two transdermal drug delivery methods. Altogether, our findings show that pre-treatment of microneedle arrays can enhance transdermal delivery efficiency of pilocarpine to human eccrine sweat glands.<br />Competing Interests: Declaration of competing interest Ying-Shu Quan and Hirofumi Yamashita are employees of CosMED Pharmaceutical Co. Ltd. The views expressed in this manuscript do not represent those of the company. Microneedles array was supplied by CosMED Pharmaceutical Co. Ltd. without any financial support. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1873-3476
Volume :
662
Database :
MEDLINE
Journal :
International journal of pharmaceutics
Publication Type :
Academic Journal
Accession number :
39033941
Full Text :
https://doi.org/10.1016/j.ijpharm.2024.124497